Effect of erythropoietin on the migration of bone marrow-derived mesenchymal stem cells to the acute kidney injury microenvironment

Liu, Nanmei; Tian, Jun; Cheng, Jin; Zhang, Jinyuan

doi:10.1016/j.yexcr.2013.04.008

Cited by 38 publications

(29 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is noteworthy that the transplanted cells will need to survive the harsh microenvironment before cell programming can occur for the replacement of damaged tissue. Hence, EPO administration before stem cell transplantation may help to condition the microenvironment for better chance of cell survival 20,35,124,125 and maximize tissue repair with smaller number of transplanted cells.…”

Section: Future Directionsmentioning

confidence: 99%

Revisiting the role of erythropoietin for treatment of ocular disorders

Ding

Leow

Munisvaradass

et al. 2016

Eye

View full text Add to dashboard Cite

Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible only in producing red blood cells in our body. However, with the discovery of the presence of EPO and EPO receptors in the retinal layers, the EPO seems to have physiological roles in the eye. In this review, we revisit the role of EPO in the eye. We look into the biological role of EPO in the development of the eye and the physiologic roles that it has. Apart from that, we seek to understand the mechanisms and pathways of EPO that contributes to the therapeutic and pathological conditions of the various ocular disorders such as diabetic retinopathy, retinopathy of prematurity, glaucoma, age-related macular degeneration, optic neuritis, and retinal detachment. With these understandings, we discuss the clinical applications of EPO for treatment of ocular disorders, modes of administration, EPO formulations, current clinical trials, and its future directions.

show abstract

Section: Future Directionsmentioning

confidence: 99%

Revisiting the role of erythropoietin for treatment of ocular disorders

Ding

Leow

Munisvaradass

et al. 2016

Eye

View full text Add to dashboard Cite

show abstract

“…In the second group (Cisplatin, CDDP), the rats were ip injected with a single dose (6 mg/kg) of CDDP (Hospira Co, Warwickshire, UK). 12 In the third group (Candesartan), the rats were supplemented with 10 mg/kg candesartan (AstraZeneca AB, Sö dertälje, Sweden) 13 for 10 days plus a single dose of CDDP (6 mg/kg) ip at day 3, 14 while in the fourth group (stem cells), the rats received the same ip single dose of CDDP and was administered BM-MSCs (2 Â 10 6 cells) by tail vein injection 15 24 h after the CDDP injection.…”

Section: Experimental Designmentioning

confidence: 99%

Renoprotective effects of angiotensin receptor blocker and stem cells in acute kidney injury: Involvement of inflammatory and apoptotic markers

Sherif

Al-Mutabagani

Alnakhli

et al. 2015

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Cisplatin, Cis-diamminedichloroplatinum (CDDP), is a platinum-based chemotherapy drug, and its chemotherapeutic use is restricted by nephrotoxicity. Inflammatory and apoptotic mechanisms play a central role in the pathogenesis of CDDP-induced acute kidney injury (AKI). The aim of this study was to compare the therapeutic potential of candesartan, angiotensin II receptor blocker, versus bone marrow-derived mesenchymal stem cells (BM-MSCs) in a rat model of CDDP-induced nephrotoxicity. Adult male Wistar rats (n ¼ 40) were divided into four groups; Normal control: received saline injection, CDPP group: received CDDP injection (6 mg/kg single dose), Candesartan group: received candesartan (10 mg/kg/day) for 10 days þ CDDP at day 3, and Stem cells group: received CDDP þ BM-MSCs intravenously one day after CDDP injection. The rats were sacrificed seven days after CDDP injection. Significant elevation in serum creatinine and urea, renal levels of tumor necrosis factor (TNF)-a and monocyte chemoattractant protein (MCP)-1, renal expressions of nuclear factor kappa B (NF-kB), p38-mitogen-activated protein kinase (MAPK), caspase-3 and Bcl-2-associated x protein (Bax) were found in CDDP-injected rats when compared to normal rats. Both candesartan and BM-MSCs ameliorated renal function and reduced significantly the inflammatory markers (TNF-a , NF-jB, p38-MAPK and MCP-1) and apoptotic markers (caspase-3 and Bax) in renal tissue after CDDP injection. Candesartan as well as BM-MSCs have anti-inflammatory and anti-apoptotic actions and they can be used as nephroprotective agents against CDDP-induced nephrotoxicity. BM-MSCs is more effective than candesartan in amelioration of AKI induced by CDDP.

show abstract

“…To date, accumulated evidence from preclinical and linical studies has confirmed that MSCs conferred biological and functional protections in diabetes, myocardium infarction, brain and spinal cord injury etc [15]. In re-sent years some experiment have reported the protective roles of MSCs in AP [16][17][18][19][20] MSCs infusion through tail vein can protect the structural integration of acinar cells, promoted pancreatic angiogenesis, significantly inhibited inflammation and attenuate acinar cell apoptosis. Sun XC found that intraperitoneal injection of MSCs exerted protective effects on pancreas and small intestine injury [21].…”

Section: Discussionmentioning

confidence: 99%

“…Plenty of studies confirmed that MSCs are able to ameliorate pancreatic injury, inhibit systemic inflammation and promote tissue repair in AP [6,7]. Other studies revealed that MSCs could relieve pancreatitis-associated kidney damage [8,9] or pancreatitis-associated lung injury [10,11]. Unfortunately, these studies did not highlight the appropriate way for the stem cells infuse in vivo.…”

Section: Introductionmentioning

confidence: 99%

Experimental Study on Bone Marrow Mesenchymal Stem Cells for the Treatment of Acute Pancreatitis in Rats

Chen¹

2018

MOJABB

View full text Add to dashboard Cite

Explored the appropriate way for bone marrow mesenchymal stem cells (bmMSCs) infuse in rat models of severe acute pancreatitis. Severe AP was induced in Sprage-Dawley rats by the sodium taurocholate bile duct retrograde injection. Rats were randomly divided into five groups: control group, SAP group, SAP +bmMSCs (tail vein) group, SAP + bmMSCs (intraperitoneal) group and SAP + bmMSCs (tail vein + intraperitoneal) group. In bmMSCs infused groups, bmMSCs labeled with DAPI were injected via the tail vein, intraperitoneal and via tail vein + intraperitoneal respectively 3 h after SAP. Rats were sacrificed on days 1, 2 and 3, and pancreatic tissues and the blood were collected. The levels of serum anti-inflammatory cytokines IL-10 and inflammatory cytokines (IL-1β, TNF-α, IL-6) were determined. Pathological changes of the pancreas (HE staining) were observed under light microscope. Positioning of DAPI labeled bmMSCs in vivo were detected under fluorescence microscope at the same time. The pancreas in SAP group showed significantly massive hemorrhage, edema, inflammation, and necrosis compared with control group. The inflammation, edema, hemorrhage and necrosis in each model of pancreatitis were reduced significantly in SAP+bmMSCs group as compared to SAP group (P<0.05). In bmMSCs transplanted group, bmMSCs remarkably reduced the levels of proinflammatory cytokines (TNF-α, IL-6, and IL-1β), on the contrary increased the levels of anti-inflammatory cytokines (IL-10) in SAP rats. Infused bmMSCs through tail vein + intraperitoneal indicate a better recovery than through tail vein or intraperitoneal alone. Compared with intraperitoneal injection method, more bmMSCs were observed to be presented in pancreas when bmMSCs were injected through tail vein + intraperitoneal or tail vein injection. In a rat model of SAP, transplantation of bm-MSCs through tail vein + intraperitoneal significantly inhibits inflammation and decreases pancreatic injury secondary to SAP. It was a better method for pancreatitis.

show abstract

Effect of erythropoietin on the migration of bone marrow-derived mesenchymal stem cells to the acute kidney injury microenvironment

Cited by 38 publications

References 31 publications

Revisiting the role of erythropoietin for treatment of ocular disorders

Revisiting the role of erythropoietin for treatment of ocular disorders

Renoprotective effects of angiotensin receptor blocker and stem cells in acute kidney injury: Involvement of inflammatory and apoptotic markers

Experimental Study on Bone Marrow Mesenchymal Stem Cells for the Treatment of Acute Pancreatitis in Rats

Contact Info

Product

Resources

About